Grifols is anticipating a period of strong growth on the back of its recently FDA-approved intravenous immunoglobulin product ...
The trial of the PanEcho software, presented at the American Heart Association (AHA) congress in Chicago, suggests that it ...
AI-powered chatbots will enhance HCP engagement, while comprehensive customer lifetime value prediction will enable more ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...
The trial of the PanEcho software, presented at the American Heart Association (AHA) congress in Chicago, suggests that it ...
Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...
In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of systemic hyperinflammatory syndrome, a rare and life-threatening immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback